Memorial Sloan Kettering Cancer Center
ESMO 2023 Insights: "MEDI5752 (Volrustomig) in the 1L Treatment of Patients With Advanced ccRCC"
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Martin Voss
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Martin Voss
Login to view comments.
Click here to Login